Rosacea
Rosacea is a chronic, relapsing inflammatory dermatosis that targets the centro-facial skin and ocular adnexa, manifesting with episodic flushing, fixed erythema, telangiectasias, papulopustules, phymatous tissue overgrowth and, in up to half of patients, blepharitis or keratoconjunctivitis. Four overlapping phenotypes are recognised—erythematotelangiectatic, papulopustular, phymatous and ocular—but modern management classifies disease by individual clinical features to direct therapy. Prevalence ranges from 1 – 10 % worldwide, peaking in fair-skinned women aged 30–50 years, yet men more often develop disfiguring rhinophyma.
Symptoms
Patients experience episodic flushing that evolves into persistent centro-facial redness, stinging or burning, coarse telangiectasias, inflammatory papules and pustules that spare the perioral vermilion border, and ocular grittiness or photophobia. Phymatous hypertrophy of sebaceous tissue—most conspicuously rhinophyma—presents later, primarily in men.
Risk Factors
Positive family history, female sex, Fitzpatrick skin phototypes I–II, Northern European ancestry, frequent ultraviolet or heat exposure, alcohol—especially white wine and liquor—spicy foods, high-glycaemic diets, emotional stress, smoking, photosensitising or topical corticosteroid use, Helicobacter pylori gastritis, small-intestinal bacterial over-growth and systemic immunosuppression all increase incidence or trigger flares.
Diagnosis
Diagnosis is clinical, requiring one diagnostic sign (fixed centro-facial erythema that worsens episodically or phymatous change) or two major signs (papulopustules, flushing, telangiectasia or ocular manifestations). Laboratory tests are unnecessary unless lupus, dermatomyositis, acne or seborrhoeic dermatitis are suspected. Dermoscopy accentuates polygonal telangiectatic networks; confocal microscopy reveals dilated follicles packed with Demodex. Skin biopsy is reserved for atypical or treatment-refractory cases.
Treatment
Therapy follows a phenotype-based algorithm. For flushing and persistent erythema, topical α-adrenergic vasoconstrictors brimonidine 0.33 % gel once daily or oxymetazoline 1 % cream reduce redness within 30 minutes. Oral non-selective β-blockers or carvedilol help refractory flushing. Papulopustular lesions respond to topical ivermectin 1 % cream, metronidazole 0.75–1 % gel, azelaic acid 15 % foam or 20 % cream, or micro-encapsulated benzoyl peroxide 5 % cream; moderate disease requires oral doxycycline 40 mg modified-release or minocycline foam, and severe nodular disease may need isotretinoin 0.3 mg/kg/day for 12–16 weeks. Rebound-safe, low-dose isotretinoin is increasingly favoured for recurrent flares. Fixed telangiectasias and background erythema improve with pulsed-dye or KTP lasers and intense-pulsed-light therapy; phymatous over-growth responds to CO₂/erbium laser resurfacing, tangential excision or radiofrequency ablation. Ocular rosacea is managed with eyelid hygiene, artificial tears, oral doxycycline and, in severe blepharokeratitis, topical cyclosporine 0.05 % drops.
Outlook
Although incurable, > 80 % of patients achieve long-term control with trigger avoidance, dedicated skin care and targeted pharmacotherapy. Untreated rosacea tends to progress from episodic flushing to fixed erythema and phymatous disfigurement; ocular complications can scar the cornea if neglected.
Complications
Corneal neovascularisation and scarring, chronic blepharitis, rhinophyma with airway or social impairment, persistent facial lymphoedema (Morbihan disease), psychosocial distress, and steroid-induced rosacea from inappropriate topical corticosteroid use.
Prevention
While primary prevention is impossible, secondary prevention hinges on meticulous trigger avoidance, early treatment of new lesions, proactive photoprotection and routine ophthalmic screening in ocular-predisposed patients. Probiotic-rich diets and treatment of SIBO show promise in reducing flare frequency but require further study.
Support
Keep a symptom diary to identify triggers; apply broad-spectrum mineral sunscreen SPF 30+ daily; use gentle, fragrance-free cleansers and moisturisers; avoid alcohol-based toners, menthol, camphor or exfoliating scrubs; cool the face after exercise; practise stress-reduction techniques; and protect facial skin in extreme cold or wind. Family or partners can assist by preparing low-spice meals, moderating indoor temperatures and reminding about medication schedules.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
